Lidia Ciszak
Overview
Explore the profile of Lidia Ciszak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kosmaczewska A, Ciszak L, Frydecka I, Pawlak E, Szteblich A, Wrobel T, et al.
Pol Arch Intern Med
. 2025 Feb;
PMID: 39950487
Introduction: A unique feature of chronic lymphocytic leukemia (CLL) is the increased number of circulating T cells preventing malignant B cells from undergoing apoptosis. Dysregulated expression of p27Kip1 and cyclin...
2.
Ciszak L, Kosmaczewska A, Pawlak E, Frydecka I, Szteblich A, Wolowiec D
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519258
Beyond the essential role of p27 and cyclin D2 in cell cycle progression, they are also shown to confer an anti-apoptotic function in peripheral blood (PB) lymphocytes. Although the aberrant...
3.
Kulikowska de Nalecz A, Ciszak L, Usnarska-Zubkiewicz L, Pawlak E, Frydecka I, Szmyrka M, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982802
Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of...
4.
Karabon L, Andrzejczak A, Ciszak L, Tomkiewicz A, Szteblich A, Bojarska-Junak A, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831232
In our previous study, while chronic lymphocytic leukemia (CLL) cases showed higher levels of B and T lymphocyte attenuator (BTLA) mRNA compared to controls, lower BTLA protein expression was observed...
5.
Kulikowska de Nalecz A, Ciszak L, Usnarska-Zubkiewicz L, Frydecka I, Pawlak E, Szmyrka M, et al.
Int J Mol Sci
. 2021 Sep;
22(17).
PMID: 34502204
Unlike solid-tumor patients, a disappointingly small subset of multiple myeloma (MM) patients treated with checkpoint inhibitors derive clinical benefits, suggesting differential participation of inhibitory receptors involved in the development of...
6.
Kosmaczewska A, Przezdziecka-Dolyk J, Turno-Krecicka A, Ciszak L, Szteblich A, Wegrzyn A, et al.
Mediators Inflamm
. 2020 Aug;
2020:9175083.
PMID: 32801998
Results: In patients, an increase in the population of Th17-secreting cells negatively correlated with the abundance of both IFN--producing and T regulatory as well as suppressor cells, regarding all the...
7.
Kosmaczewska A, Ciszak L, Stosio M, Szteblich A, Madej M, Frydecka I, et al.
Lupus
. 2020 Apr;
29(7):705-714.
PMID: 32279585
Background: Pathogenic CD4CD28 cells are characterized by inflammatory cytokine synthesis and tropism to the inflamed tissues. Recent studies showed the involvement of CD28 T cells in a severe clinical outcome...
8.
Szmyrka M, Ciszak L, Weglarz M, Andrzejewska K, Wiland P, Kosmaczewska A
Pol Arch Intern Med
. 2018 Sep;
128(10):626-630.
PMID: 30238931
No abstract available.
9.
Ciszak L, Frydecka I, Wolowiec D, Szteblich A, Kosmaczewska A
Tumour Biol
. 2015 Oct;
37(3):4143-57.
PMID: 26490985
Recently, systemic administration of a human monoclonal antibody directed against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on circulating T cells in patients with chronic lymphocytic leukaemia (CLL) has been...
10.
Ciszak L, Frydecka I, Wolowiec D, Szteblich A, Kosmaczewska A
Clin Exp Med
. 2015 May;
16(3):317-32.
PMID: 26003188
Previously, we showed that cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is overexpressed in chronic lymphocytic leukaemia (CLL) and its expression is correlated with the expression of the major regulators of G1...